[go: up one dir, main page]

AU2001260880A1 - Pharmaceutical compounds for treating copd - Google Patents

Pharmaceutical compounds for treating copd

Info

Publication number
AU2001260880A1
AU2001260880A1 AU2001260880A AU6088001A AU2001260880A1 AU 2001260880 A1 AU2001260880 A1 AU 2001260880A1 AU 2001260880 A AU2001260880 A AU 2001260880A AU 6088001 A AU6088001 A AU 6088001A AU 2001260880 A1 AU2001260880 A1 AU 2001260880A1
Authority
AU
Australia
Prior art keywords
pharmaceutical compounds
treating copd
copd
treating
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001260880A
Inventor
Anthony J. Kettle
Kam-Wah Thong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2001260880A1 publication Critical patent/AU2001260880A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Use of an MPO inhibitor for the treatment of COPD.
AU2001260880A 2000-05-12 2001-05-08 Pharmaceutical compounds for treating copd Abandoned AU2001260880A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0011358A GB2362101A (en) 2000-05-12 2000-05-12 Treatment of chronic obstructive pulmonary disease
GB0011358 2000-05-12
PCT/SE2001/001014 WO2001085146A1 (en) 2000-05-12 2001-05-08 Pharmaceutical compounds for treating copd

Publications (1)

Publication Number Publication Date
AU2001260880A1 true AU2001260880A1 (en) 2001-11-20

Family

ID=9891383

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001260880A Abandoned AU2001260880A1 (en) 2000-05-12 2001-05-08 Pharmaceutical compounds for treating copd

Country Status (10)

Country Link
US (1) US20040029871A1 (en)
EP (1) EP1294366B1 (en)
JP (1) JP2004509841A (en)
CN (1) CN1427718A (en)
AT (1) ATE273699T1 (en)
AU (1) AU2001260880A1 (en)
CA (1) CA2406512A1 (en)
DE (1) DE60105025T2 (en)
GB (1) GB2362101A (en)
WO (1) WO2001085146A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147216A1 (en) * 2000-01-31 2002-10-10 Yuhong Zhou Mucin synthesis inhibitors
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
CA2398642A1 (en) * 2000-01-31 2001-08-02 Yuhong Zhou Mucin synthesis inhibitors
SE0103766D0 (en) * 2001-11-09 2001-11-09 Astrazeneca Ab Novel assay
AR039385A1 (en) 2002-04-19 2005-02-16 Astrazeneca Ab THIOXANTINE DERIVATIVES AS INHIBITORS OF MIELOPEROXIDASA
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
SE0301232D0 (en) * 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
MXPA03006549A (en) * 2003-07-22 2004-03-18 Univ Autonoma Metropolitana Use of dapsone as neuroprotective in cerebral infarction.
SE0302756D0 (en) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
SE0402591D0 (en) * 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
CA2687715A1 (en) * 2007-05-09 2008-11-20 Traffick Therapeutics Inc. Screening assay to identify correctors of protein trafficking defects
EP2671614A1 (en) * 2007-12-21 2013-12-11 University of Rochester Molecular Targets for Treatment of Inflammation
US20130005822A1 (en) * 2010-03-15 2013-01-03 Rubin Bruce K Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport
US20110287468A1 (en) 2010-04-19 2011-11-24 General Atomics Methods and compositions for assaying enzymatic activity of myeloperoxidase in blood samples
EP2654749B1 (en) * 2010-12-23 2017-05-10 The Board of Regents of The University of Texas System Methods for treating copd
BR112014011254A2 (en) 2011-11-11 2017-05-16 Pfizer 2-thiopyrimidinones
EP2682119A1 (en) * 2012-07-03 2014-01-08 Université Libre de Bruxelles Aromatic N-heterocycle derivatives for use as medicine
AU2016257179A1 (en) 2015-05-05 2017-11-02 Pfizer Inc. 2-thiopyrimidinones
EP3654983B1 (en) * 2017-07-17 2023-08-30 Astrazeneca AB Mpo inhibitors for use in medicine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL314605A1 (en) * 1993-11-26 1996-09-16 Pfizer Isoxazolin compounds as anti-inflammatory agents
US5708009A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
US5447941A (en) * 1993-12-21 1995-09-05 Eli Lilly And Company Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
IL120268A0 (en) * 1996-02-28 1997-06-10 Pfizer Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
AU4084599A (en) * 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase
DZ3019A1 (en) * 1999-03-01 2005-05-20 Smithkline Beecham Corp Use of a pde4 inhibitor in the preparation of a drug against copd.

Also Published As

Publication number Publication date
JP2004509841A (en) 2004-04-02
WO2001085146A1 (en) 2001-11-15
ATE273699T1 (en) 2004-09-15
CA2406512A1 (en) 2001-11-15
EP1294366A1 (en) 2003-03-26
EP1294366B1 (en) 2004-08-18
CN1427718A (en) 2003-07-02
US20040029871A1 (en) 2004-02-12
GB2362101A (en) 2001-11-14
DE60105025D1 (en) 2004-09-23
GB0011358D0 (en) 2000-06-28
DE60105025T2 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
MXPA03007140A (en) Chemical compounds.
WO2003042246A3 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
WO2002030353A3 (en) NF-λB INHIBITORS
AU7031500A (en) Therapeutic quinazoline compounds
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU2002338807A1 (en) Use of c-kit inhibitors for the treatment of myeloma
DK1206474T3 (en) Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors
AU2001230395A1 (en) Use of cox-2 inhibitors as gastroprokinetics
AU2002249890A1 (en) Carboline derivatives
AU2001266575A1 (en) Chemical compounds
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
AU2002218439A1 (en) Apparatus for treating body ailments
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
MXPA04003755A (en) Stents.
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
GB9907571D0 (en) Compounds
AP2001002248A0 (en) Method for treating COPD.
AU2001232060A1 (en) Use of cyp1b1 inhibitors for treating cancer
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers